相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial
Mhairi Copland et al.
LANCET HAEMATOLOGY (2022)
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors
Fadi G. Haddad et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors
Justin Shaya et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
Koji Sasaki et al.
BLOOD (2021)
Dose Modification Dynamics of Ponatinib in Patients with Chronic- Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials
Elias J.Jabbour et al.
BLOOD (2021)
Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
Jiang Qian et al.
BLOOD (2021)
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
Hagop M. Kantarjian et al.
LEUKEMIA (2021)
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
Kazunori Murai et al.
Lancet Haematology (2021)
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
Yotaro Ochi et al.
NATURE COMMUNICATIONS (2021)
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
Jorge Cortes et al.
BLOOD (2021)
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Delphine Rea et al.
BLOOD (2021)
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
Kiran Naqvi et al.
CANCER (2020)
Long-term results of frontline dasatinib in chronic myeloid leukemia
Abhishek Maiti et al.
CANCER (2020)
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
Lucia Masarova et al.
CANCER (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study.
Tim H. Brümmendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
Kerstin N Vokinger et al.
LANCET ONCOLOGY (2020)
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
Jorge E. Cortes et al.
LEUKEMIA (2020)
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
Yasmin Abaza et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Andreas Hochhaus et al.
LEUKEMIA (2020)
Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors
Koji Sasaki et al.
BLOOD (2020)
Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors
Koji Sasaki et al.
BLOOD (2020)
Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
Tim H. Brummendorf et al.
BLOOD (2020)
Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial
Jorge E. Cortes et al.
BLOOD (2020)
Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212
Itaru Matsumura et al.
BLOOD (2020)
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
Georgios Nteliopoulos et al.
HAEMATOLOGICA (2019)
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
Iman Abou Dalle et al.
CANCER MEDICINE (2019)
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
Ya-Chen Tina Shih et al.
LANCET HAEMATOLOGY (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation
Chihiro Yamamoto et al.
BLOOD ADVANCES (2019)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
Susan Branford et al.
BLOOD (2018)
Early results of lower dose dasatinib (50mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
Kiran Naqvi et al.
CANCER (2018)
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
David M. Ross et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
T. P. Hughes et al.
LEUKEMIA (2017)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
A. Hochhaus et al.
LEUKEMIA (2017)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
R. Hehlmann et al.
LEUKEMIA (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Prognostic Factors and Survival Outcomes in Patients With Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients
Preetesh Jain et al.
CANCER (2017)
Overall Survival With Ponatinib Versus Allogeneic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemias With the T315I Mutation
Franck E. Nicolini et al.
CANCER (2017)
Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest
Madhav Danthala et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry
Tomasz Sacha et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake et al.
BLOOD (2017)
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
Neil P. Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Monitoring and defining early response: Where to draw the line?
Susan Branford
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States
Gregory H. Jones et al.
BLOOD (2016)
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Wei Wang et al.
BLOOD (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z. Carter et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
Jorge E. Cortes et al.
LANCET HAEMATOLOGY (2016)
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
Jianxiang Wang et al.
BLOOD (2015)
Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?
Hagop Kantarjian et al.
MAYO CLINIC PROCEEDINGS (2015)
Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico
Jose Carlos Jaime-Perez et al.
ONCOLOGIST (2015)
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
Preetesh Jain et al.
LANCET HAEMATOLOGY (2015)
Having Skin in the Game and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs
Hagop Kantarjian et al.
JAMA ONCOLOGY (2015)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Timothy P. Hughes et al.
BLOOD (2014)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
Paolo Gallipoli et al.
BLOOD (2014)
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Susan Branford et al.
BLOOD (2014)
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
Neil P. Shah et al.
BLOOD (2014)
HCVAD Plus Imatinib or Dasatinib in Lymphoid Blastic Phase Chronic Myeloid Leukemia
Paolo Strati et al.
CANCER (2014)
Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Maro Ohanian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
WHAT IS THE MOST COST-EFFECTIVE STRATEGY FOR TREATING CHRONIC MYELOID LEUKEMIA AFTER IMATINIB LOSES PATENT EXCLUSIVITY IN EUROPE?
W. Padula et al.
VALUE IN HEALTH (2014)
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
Tun Kiat Ko et al.
ONCOTARGET (2014)
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Preetesh Jain et al.
BLOOD (2013)
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Pratap Neelakantan et al.
BLOOD (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Advances in Immunotherapy of Chronic Myeloid Leukemia CML
Stefanie Erika Held et al.
CURRENT CANCER DRUG TARGETS (2013)
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months
Aziz Nazha et al.
HAEMATOLOGICA (2013)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F. J. Giles et al.
LEUKEMIA (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian et al.
BLOOD (2012)
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
Jerald P. Radich et al.
BLOOD (2012)
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Xuelin Huang et al.
CANCER (2012)
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
David Montani et al.
CIRCULATION (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
P. D. le Coutre et al.
LEUKEMIA (2012)
Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy
Michael Schnekenburger et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
Elias Jabbour et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Elias Jabbour et al.
CANCER (2011)
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Considerations in the Management of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Hagop Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
Elias Jabbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Ruediger Hehlmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.
Claude Preudhomme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Elias Jabbour et al.
BLOOD (2009)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Martin C. Mueller et al.
BLOOD (2009)
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Nicoletta Testoni et al.
BLOOD (2009)
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Bleeding Diathesis in Patients With Chronic Myelogenous Leukemia Receiving Dasatinib Therapy
Alfonso Quintas-Cardama et al.
CANCER (2009)
Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid Leukemia
Alfonso Quintas-Cardama et al.
CANCER (2009)
Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily Two-Year Follow-Up of a Randomized Phase 2 Study (START-R)
Hagop Kantarjian et al.
CANCER (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Jane F. Apperley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Stephanie J. Lee et al.
BLOOD (2008)
Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era:: SCT or TKIs?
G. J. Ruiz-Argulles et al.
BONE MARROW TRANSPLANTATION (2008)
Molecular monitoring in chronic myeloid leukemia - Response to tyrosine kinase inhibitors and prognostic implications
Elias Jabbour et al.
CANCER (2008)
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Hagop Kantarjian et al.
BLOOD (2008)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia - No evidence for increased transplant-related toxicity
Elias Jabbour et al.
CANCER (2007)
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
Paul A. Carpenter et al.
BLOOD (2007)
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
Vivian G. Oehler et al.
BLOOD (2007)
Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukaemia
Theodore Darkow et al.
PHARMACOECONOMICS (2007)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour et al.
BLOOD (2006)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Results of decitabine (5-Aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
HM Kantarjian et al.
CANCER (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases
C Schoch et al.
LEUKEMIA (2002)
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
BJ Druker et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
